COVID-19 Progression in End-Stage Kidney Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

412 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-08-06

Study Completion Date

2021-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to collect genomic and clinical data among a cohort of hemodialysis patients and analyze the association between genetic markers and the development and severity of illness in response to SARS-CoV-2.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Kidney Disease After COVID-19

NCT05328986

COVID-19 Acute Kidney Injury Chronic Kidney Injury

COMPLETED

Kidney Precision Medicine Project (KPMP) - COVID-19 Protocol

NCT05384899

Acute Kidney Failure Acute Kidney Insufficiency Acute Renal Failure +8 more

UNKNOWN

Phenotyping Seroconversion Following Vaccination Against COVID-19 in Patients on Haemodialysis Study

NCT04815850

End Stage Kidney Disease

COMPLETED

Kidney Disease Biomarkers

NCT00255398

Kidney Disease Glomerular Disease Idiopathic Nephrotic Syndrome +2 more

COMPLETED

Serological Testing for COVID-19 (SARS-CoV-2) in ESKD

NCT04378686

SARS-CoV 2 End Stage Renal Failure on Dialysis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

COVID-19 is a novel illness caused by the SARS-CoV-2 virus. It was declared as a global pandemic on March 11, 2020 and since that time there have been outbreaks on every continent except for Antarctica. Preliminary understanding of the virus suggests that some fraction of the population does not manifest clinical disease in response to infection, others manifest a relatively benign course of illness, and still others develop a fulminant course that eventuates in the need for intensive care, mechanical ventilation, or even death. The genetic and epigenetic basis for differential susceptibility remains unknown.

Patients receiving hemodialysis provide a good opportunity to understand genetic and epigenetic susceptibility to SARS-CoV-2. By virtue of their ongoing requirements for care, such patients cannot shelter at home or maintain social distancing, but must instead report to a clinical care setting on a thrice weekly basis. Moreover, such patients often travel to and from dialysis using shared ride services, which furthers opportunity for exposure. Preliminary estimates suggest that rates of SARS-CoV-2 positivity are 2 to 5-fold higher among hemodialysis patients than in the general public. Furthermore, frequent contact with the health care system among dialysis patients makes tracking clinical course comparatively easy.

The purpose of this study is to collect genomic and clinical data among a cohort of hemodialysis patients and analyze the association between genetic markers and the development and severity of illness in response to SARS-CoV-2.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

SARS-CoV-2 Infection (Asymptomatic) SARS-CoV-2 Infection (Symptomatic)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group I

Group I- Asymptomatic patients with SARS-CoV-2 Infection

No interventions assigned to this group

Group II

Group II-Symptomatic patients with SARS-CoV-2 Infection

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Is 18 years or older at the time of consent
* Ability to provide informed consent.
* Is currently receiving hemodialysis treatment for end-stage kidney disease at a DaVita dialysis center.
* Enrollment in prior genomics study (Additional criteria for type B only)

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No